Bioequivalence of olmesartan medoxomil tablets in Chinese healthy subjects in fasting state

doi:10.12092/j.issn.1009-2501.2020.01.010

Abstract

Abstract: AIM: To investigate the bioequivalence of domestic olmesartan medoxomil tablets and imported olmesartan medoxomil tablets (Benicar) in Chinese healthy subjects in fasting state. METHODS: This is an open, random and two-way crossover clinical trial involved 24 healthy subjects. A single oral dose 20 mg of domestic olmesartan medoxomil tablets (test preparation) and imported olmesartan medoxomil tablets (control preparation) was administrated under the condition of fasting. The plasma concentrations of olmesartan were determined by LC-MS/MS. The pharmacokinetics parameters were calculated and the bioequivalence of two formulations were evaluated by WinNonlin7.0 program. RESULTS:The main pharmacokinetic parameters of the test and control preparation were as follows: Cmax (702.08±149.24) vs.(706.50±127.00) μg/L; tmax 1.98 (1.33-4.00) vs. 1.98 (1.33-3.50) h; AUC0-t (4 516.93±995.07) vs. (4 543.74±818.45) μg·h·L-1; AUC0-∞ (4 578.16±1 005.73) vs. (4 605.70±820.54) μg·h·L-1;t1/2 (8.00±1.07) vs. (7.94±1.30) h, respectively. The 90% confidence limit of test preparation of the logarithmic transformed parameters Cmax, AUC0-t and AUC0-∞ were in 92.33%-105.29%, 91.86%-105.26%, 91.89%-105.16% vs. the reference preparation, respectively.CONCLUSION: The developed and validated method is rapid, sensitive, selective and reliable for the determination of olmesartan in human plasma; the domestic olmesartan medoxomil tablets are bioequivalence to the imported olmesartan medoxomil tablets.

Key words: olmesartan medoxomil, pharmacokinetic parameters, bioequivalence, liquid chromatography/tandem mass spectrometry

CLC Number:

R969.1

XU Meiyan, WU Wei, LI Cui. Bioequivalence of olmesartan medoxomil tablets in Chinese healthy subjects in fasting state[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 68-74.

References

［1］Warner GT, Jarvis B. Olmesartan medoxomil［J］. Drugs, 2002, 62(13): 1354-1356.
［2］封宇飞，雷静，吕俊玲，等．新一代血管紧张素受体阻断剂奥美沙坦酯［J］. 中国新药杂志，2003, 12(7): 520-523.
［3］Eter N, Krohne TU, Holz FG, New pharmacologic approaches to therapy for age-related macular degeneration. BioDrugs: Clinical immunotherapeutics［J］. Biopharm Gene Ther, 2006,20(3)：167-179.
［4］Schwocho LR, Masonson HN, Pharmacokinetics of CS-866, a new angiotensin Ⅱreceptor blocker, in healthy subjects［J］. Clin Pharmacol, 2001, 41(5): 515-527.
［5］Kobayashi N, Fujimori I, Watanbe M, et al. Real-time monitoring of metabolic reaction by microdialysis in combination with tadem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines［J］. Analytic Biochem, 2000, 287:272-278.
［6］Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin Ⅱreceptor antagonist［J］. Eur J Pharmacol, 1995, 285(2)：181-188.
［7］蒋娟娟，田蕾，黄一玲，等．奥美沙坦酯片人体生物等效性研究［J］. 中国新药杂志，2007, 16(12): 976-979.
［8］张小丽，于洋，侯艳宁，等．人血浆中奥美沙坦的HPLC-MS/MS测定［J］. 中国医药工业杂志，2006, 37(10): 697-699.
［9］于洋，侯艳宁，刘建芳，等．固相萃取结合HPLC-MS测定人血浆中奥美沙坦酯的药物质量浓度［J］. 药学杂志，2006, 41(20): 1592-1593.
［10］Gu SF, Chen H, Qiu YH, et al. Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers［J］. J Huaz hong Univ Sci Technol(Med Sci), 2002, 22(1): 14-16.
［11］杨瑞虹．新型降压药奥美沙坦酯［J］. 临床医药实践，2005, 14(9): 645-647.

[1]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[2]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[3]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[4]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[5]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.
[6]	SHI Gexin, CHONG Rui, HE Kun, WU Haitang, ZHOU Yu, DUN Zhongjun, WEN Qing, ZHANG Jiguo, ZHANG Rong. A fully replicated crossover bioequivalence study of mycophenolate mofetil capsules in Chinese healthy male subjects under fasting and fed conditions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1255-1263.
[7]	GAO Rong, MA Yazhong, ZHAO Haixia, WANG Zhaoyuan, ZHANG Weihong, YUAN Hailong. Bioequivalence of amlodipine besylate tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 56-62.
[8]	HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang. Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
[9]	CAI Mingmin, SHAO Jing, TANG Lu, SUN Qiuyue, DOU Ting, QIAN Wei, WANG Huiping. Bioequivalence study of buthlphthalide injection in Chinese healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 70-76.
[10]	ZHENG Binjie, LIU Na, ZENG Xiangchang, HUANG Xinyi, CHEN Lulu, OU-YANG Dongsheng. Effects of gut microbiota on pharmacokinetics and its consideration in the evaluation of the consistency of quality and efficacy of generic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 662-671.
[11]	SUN Yuchen, LIU Yinhui, ZHANG Xian, YUAN Tong, JING Mengyao, ZAHNG Xinyu, YANG Jin. Exploration of screening criteria for healthy volunteers in human bioequivalence clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 714-720.
[12]	LI Xiaomin, JIN Hao, ZHOU Wenzhi, YANG Hanyue, ZOU Ting, GUO Jie, XU Pingsheng. Bioequivalence of metformin hydrochloride sustained-release tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 408-413.
[13]	WANG Hui, CUI Chang, YANG Shuang, YAO An, WU Shuting, YANG Xiaoyan, YE Ling, ZOU Zhi, TANG Zhi, YANG Guoping, HUANG Jie, OUYANG Dongsheng. Bioequivalence of solifenacin succinate tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 299-304.
[14]	WANG Xiaoru, ZHANG Xueyuan, WANG Xiaoyan, YANG Hanyu. Bioequivalence study of pramipexole hydrochloride tablets in Chinese healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 190-195.
[15]	LIU Chang, DENG Kunhong, HUANG Jie, YANG Shuang, YANG Xiaoyan, XIANG Yuxia, HUANG Lu, ZHANG Zeyu, LIANG Wenzhong, LAN Jing, YANG Guoping. Bioequivalence of moxifloxacin hydrochloride tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1393-1399.